US · Healthcare · Biotechnology
EPS came in at 7.80 against a street estimate of 7.44 — a beat of 4.8%.
Analysts rate argenx NV ADR a buy (20 buy, 3 hold, 0 sell out of 23) with an average price target of $1,147.35.
| Fund | Stake |
|---|---|
| FMR Inc | 8.32% |
| T. Rowe Price Associates, Inc. | 4.26% |
| Jupiter Topco LLC | 3.93% |
| Capital World Investors | 3.50% |
| Artisan Partners Limited Partnership | 2.40% |
| venBio Select Advisor LLC | 1.59% |
| Wellington Management Company LLP | 1.48% |
| BlackRock Inc | 1.24% |
| Document | Date |
|---|---|
| Quarterly results (6-K) · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 global VYVGART product net sales were $1.7 billion, up 54% year over year and 13% quarter over quarter. • Thir | 2026-10-22 |
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • Phase 3 ALKIVIA met its primary endpoint in autoimmune myositis, with efgartigimod delivering a 15.4-point greater improvement in | 2026-10-19 |
| Current report (6-K) · Q4 2026 OTHER NOTABLE POINTS • argenx SE filed a Form 6-K with the U.S. Securities and Exchange Commission for the month of October 2026. • On October 8, 20 | 2026-10-08 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • argenx presented new clinical, long-term and real-world data for VYVGART, empasiprubart and adimanebart at the 2026 AANEM Annual M | 2026-09-29 |
| Current report (6-K) · Q3 2026 OTHER NOTABLE POINTS • argenx SE filed a Form 6-K with the U.S. Securities and Exchange Commission for August 2026. • The filing states that the com | 2026-08-27 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • argenx reported positive topline results from the Phase 3 ALKIVIA trial of VYVGART Hytrulo (efgartigimod) in autoimmune myositis. | 2026-08-17 |
| Current report (6-K) · Q3 2026 OTHER NOTABLE POINTS • argenx SE filed a Form 6-K with the U.S. Securities and Exchange Commission for the month of August 2026. • The filing relate | 2026-08-03 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • argenx agreed to acquire Forte Biosciences for $77 per share in cash, implying a total equity value of approximately $2.2 billion. | 2026-07-27 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for argenx NV ADR — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.